-Inclusion Criteria:  Primary Objective Cohort  Treatment naïve patients with histologically confirmed clinically significant prostate cancer (defined as Gleason score > 3+4 and a maximum cancer core length of > 4mm (42)) with a clinical indication for prostate mpMRI for pre-treatment tumor detection and staging Patients with anticipated clinical follow-up who are anticipated to undergo surgery at MD Anderson.  Secondary Objective Cohort  Treatment naïve patients with histologically confirmed intermediate risk prostate cancer (defined as Gleason score > 3+4 and a maximum cancer core length of > 4mm (42)) with a clinical indication for prostate mpMRI, who are to undergo target selection for fusion guided biopsy. Patients who are anticipated to undergo fusion guided biopsy at MD Anderson.  Exclusion Criteria:  Patients who have already received androgen deprivation therapy or undergone prior surgery, radiotherapy or focal ablative therapies to the prostate Patients whose weight exceeds 400 pounds Patients allergic to gadolinium Patients with pacemakers or other implantable devices or conditions that are a contraindication to MRI Patients with conditions precluding MR imaging at 3T Patients less than 18 years of age Patients unable to provide informed consent Patients unable to tolerate an endorectal coil Patients who have undergone prostate biopsy less than 6 weeks prior to their MRI